KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ginkgo Bioworks Holdings (DNA) EBT Margin (2020 - 2025)

Ginkgo Bioworks Holdings filings provide 6 years of EBT Margin readings, the most recent being 243.72% for Q4 2025.

  • On a quarterly basis, EBT Margin rose 227.0% to 243.72% in Q4 2025 year-over-year; TTM through Dec 2025 was 184.3%, a 5684.0% increase, with the full-year FY2025 number at 184.3%, up 5684.0% from a year prior.
  • EBT Margin hit 243.72% in Q4 2025 for Ginkgo Bioworks Holdings, down from 207.93% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 63.76% in Q3 2024 to a low of 1081.31% in Q4 2021.
  • Median EBT Margin over the past 5 years was 244.86% (2024), compared with a mean of 352.27%.
  • Biggest five-year swings in EBT Margin: crashed -93660bps in 2021 and later skyrocketed 89018bps in 2022.
  • Ginkgo Bioworks Holdings' EBT Margin stood at 1081.31% in 2021, then skyrocketed by 82bps to 191.13% in 2022, then plummeted by -219bps to 609.67% in 2023, then surged by 60bps to 245.99% in 2024, then increased by 1bps to 243.72% in 2025.
  • The last three reported values for EBT Margin were 243.72% (Q4 2025), 207.93% (Q3 2025), and 122.13% (Q2 2025) per Business Quant data.